{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:21:37Z","timestamp":1790871697629,"version":"4.1.0"},"reference-count":28,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2008,1,11]],"date-time":"2008-01-11T00:00:00Z","timestamp":1200009600000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Eur J of Neuroscience"],"published-print":{"date-parts":[[2008,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Administration of VP025 (Vasogen Inc.), a novel drug formulation based on phospholipid nanoparticles incorporating phosphatidylglycerol, has previously been shown to have a neuroprotective effect in the brain. We examined the effect of VP025 in a rat model of Parkinson's disease, the 6\u2010hydroxydopamine (6\u2010OHDA) lesion of the medial forebrain bundle. VP025 or phosphate\u2010buffered saline (PBS) was administered to rats 14\u2003days, 13\u2003days and 1\u2003day before the unilateral 6\u2010OHDA lesion. Functional integrity of nigrostriatal dopaminergic neurons was assessed 7 and 21\u2003days later by amphetamine\u2010induced rotational testing and we observed that rotational counts were significantly less in rats that were pretreated with VP025 compared with PBS\u2010pretreated 6\u2010OHDA\u2010lesioned rats. Neurochemical analysis at 10 and 28\u2003days after lesion revealed that VP025 protected against a 6\u2010OHDA\u2010induced decrease in concentrations of striatal dopamine and its metabolites. Immunocytochemical studies of the ipsilateral substantia nigra showed that VP025 significantly inhibited 6\u2010OHDA\u2010induced loss of dopaminergic neurons. We also observed that increases in immunostaining for activated microglia and for activated p38 in dopaminergic neurons of 6\u2010OHDA\u2010lesioned rats were prevented by VP025. This study shows that VP025 has significant protective effects on the 6\u2010OHDA\u2010lesioned nigrostriatal pathway and may therefore have potential for the treatment of Parkinson's disease.<\/jats:p>","DOI":"10.1111\/j.1460-9568.2007.06018.x","type":"journal-article","created":{"date-parts":[[2010,7,19]],"date-time":"2010-07-19T15:55:50Z","timestamp":1279554950000},"page":"294-300","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Neuroprotective effects of novel phosphatidylglycerol\u2010based phospholipids in the 6\u2010hydroxydopamine model of Parkinson's disease"],"prefix":"10.1111","volume":"27","author":[{"given":"S.","family":"Crotty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Fitzgerald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Tuohy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. M.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Mandel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. E.","family":"Bolton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. M.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Nolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,1,18]]},"reference":[{"key":"e_1_2_7_2_1","first-page":"134.11","article-title":"Novel phospholipid\u2010based drug formulation reduces neuroinflammation and slows disease in a mouse model of amyotrophic lateral sclerosis","author":"Beers D.R.","year":"2004","journal-title":"Society for Neuroscience Abstracts"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(06)70373-8"},{"key":"e_1_2_7_4_1","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1046\/j.1460-9568.2002.01938.x","article-title":"Neuroinflammation of the nigrostriatal pathway during progressive 6\u2010OHDA DOPA degeneration in rats monitored by immunohistochemistry and PET imaging","volume":"15","author":"Chicchetti F.","year":"2002","journal-title":"Eur. J. Neurosci."},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M311164200"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(03)00351-X"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI1112"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa033447"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.2002.00928.x"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2006.04165.x"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M306735200"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(01)02681-6"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI0211638"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.20-16-06309.2000"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.46.3.678"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2004.07.002"},{"key":"e_1_2_7_17_1","unstructured":"Martin D.S.D. Walsh M. Miller A.M. Nolan Y. Mandel A. Bolton A.E.&Lynch M.A.(2005a)The age\u2010related increase in microglial activation in the rat hippocampus is abrogated by a novel phospholipid\u2010based drug formulation.Soc. Neurosci. Abstract 910.2."},{"key":"e_1_2_7_18_1","unstructured":"Martin D.S.D. Walsh M. Miller A.M. Nolan Y. Mandel A. Bolton A.E.&Lynch M.A.(2005b)A novel phospholipid\u2010based drug formulation inhibits the age\u2010 and LPS\u2010 related increases in microglial activation.British Neurosci. Assoc. Abstracts 8.05."},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1113\/expphysiol.1991.sp003533"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01191700"},{"key":"e_1_2_7_21_1","unstructured":"Miller A.M. Piazza A. Walsh M. Martin D.S.D. Mandel A. Bolton A.E.&Lynch M.A.(2005)A novel phospholipid\u2010based drug formulation inhibits the acute and chronic effects of \u2010amyloid administration on long\u2010term potentiation and microglia activation in rat hippocampus.Soc. Neurosci. Abstract 910.3."},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s007020050028"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3940(99)00388-2"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2004.02.001"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-4886(03)00301-7"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20457"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16305-8"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2004.035980"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1460-9568.1998.00378.x"}],"container-title":["European Journal of Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1460-9568.2007.06018.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1460-9568.2007.06018.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T00:59:36Z","timestamp":1696899576000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1460-9568.2007.06018.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,1]]}},"alternative-id":["10.1111\/j.1460-9568.2007.06018.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1460-9568.2007.06018.x","archive":["Portico"],"relation":{},"ISSN":["0953-816X","1460-9568"],"issn-type":[{"value":"0953-816X","type":"print"},{"value":"1460-9568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1]]},"assertion":[{"value":"2008-01-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}